Hims & Hers will launch an AI companion for weight-loss journey support, CTO Mo Elshenawy announced Monday. The agent targets users on GLP-1 medications as demand surges.
Key facts
- Hims & Hers Q1 2026 revenue grew 25% to $420 million.
- AI agent targets users on GLP-1 medications like semaglutide.
- CTO Mo Elshenawy announced the launch during earnings call.
- The company says the agent will launch 'soon'.
- Hims & Hers competes with Noom, Ro, and WeightWatchers.
Hims & Hers Health (NYSE: HIMS) will launch an AI companion designed to support users through their weight-loss journey, the company announced during its Q1 2026 earnings call on Monday. CTO Mo Elshenawy highlighted the company's AI investments, positioning the agent as a tool to engage users on GLP-1 medications.
The AI agent, set to launch "soon" according to the company, will focus on adherence and personalized guidance for patients using GLP-1 drugs like semaglutide and tirzepatide. The move comes as Hims & Hers reported continued interest in GLP-1 usage, despite broader market uncertainty around compounding pharmacies and regulatory shifts.
Why This Matters More Than a Feature Launch
The unique angle here isn't the AI agent itself — it's the strategic pivot. Hims & Hers, a telehealth company, is using AI to deepen engagement with its highest-value cohort: GLP-1 users. This is a retention play, not a discovery one. By embedding an AI companion into the weight-loss journey, the company aims to reduce churn and increase lifetime value per patient, potentially offsetting the high acquisition costs of GLP-1 customers.
This contrasts with typical AI agent rollouts in healthcare, which focus on triage or scheduling. Hims & Hers is betting on continuous, context-aware coaching — a model that could extend beyond weight loss to other chronic conditions like hypertension or diabetes.
Competitive Context
Hims & Hers competes with Ro, Noom, and WW International (WeightWatchers), all of which have integrated AI into their offerings. Noom launched a GPT-4-powered coach in 2024, while WW acquired Sequence, a GLP-1 prescribing platform. Hims & Hers's AI agent is notable for being native to its own prescription ecosystem, potentially offering tighter integration between medication management and behavioral support.
Financial Implications
The company did not disclose the cost of the AI initiative or its expected impact on margins. However, Q1 2026 revenue grew 25% year-over-year to $420 million, driven largely by GLP-1 prescriptions. Analysts will watch whether the AI agent can improve adherence rates, which directly affect recurring revenue from monthly medication subscriptions.
What to Watch
Watch for the AI agent's launch date and whether it integrates with third-party wearables or lab results. Also monitor Hims & Hers's churn rate for GLP-1 users in Q3 2026 — a leading indicator of the agent's impact. Regulatory developments around compounding pharmacies remain a wildcard.
What to watch
Watch for the AI agent's launch date and whether it integrates with wearables or lab results. Also monitor Hims & Hers's churn rate for GLP-1 users in Q3 2026. Regulatory shifts around compounding pharmacies could affect the GLP-1 market.
